Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health
Cocrystal Pharma secured $5 million in gross proceeds through a private placement with OPKO Health, selling 5.47 million shares at the Nasdaq bid price of $0.9134. The investment increases OPKO's position as the company prepares to report topline data from its Phase 1b norovirus trial for lead asset CDI-988 in late 2026.
Key figures
- Deal Value Usd
- 5000000
- Offering Price
- 0.9134
- Shares Offered
- 5474053
- Drug Name
- CDI-988
- Phase Of Trial
- Phase 1b
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.